Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

EFFICACY AND SAFETY OF GZR18 INJECTED EVERY 2 WEEKS (Q2W) IN PARTICIPANTS WITHOUT TYPE 2 DIABETES, WHO HAVE OBESITY OR ARE OVERWEIGHT: A RANDOMIZED, TIRZEPATIDE- AND PLACEBO-CONTROLLED STUDY

NCT06737042 is registered in ClinicalTrials.gov with Gan and Lee Pharmaceuticals, USA as lead sponsor.

NCT NCT06737042
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06737042 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
EFFICACY AND SAFETY OF GZR18 INJECTED EVERY 2 WEEKS (Q2W) IN PARTICIPANTS WITHOUT TYPE 2 DIABETES, WHO HAVE OBESITY OR ARE OVERWEIGHT: A RANDOMIZED, TIRZEPATIDE- AND PLACEBO-CONTROLLED STUDY
Lead sponsor
Gan and Lee Pharmaceuticals, USA
Phase
Phase 2
Overall status
Completed
Start date
February 24, 2025
Completion date
February 27, 2026
Enrollment
326 (actual)
Sites
20

Conditions

As the registry lists them; a condition with its own page is linked.

obesity and overweight